There are currently 74 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Autism participants are California, Ohio, Michigan and Illinois.
Advanced Planning for Online Accounts and Data
NCT05222308
Recruiting
The proposed research consists of engagements with terminal cancer patients and their friends and family as they engage in end-of-life planning.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/13/2024
Locations: University of Colorado Health, Aurora, Colorado
Conditions: Terminal Cancer, Metastatic Cancer
Register for Updates
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626
Recruiting
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Carolina Biooncology Institute, Huntersville, North Carolina +9 locations
Conditions: Advanced Solid Tumor, Metastatic Cancer
Register for Updates
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
NCT04085029
Recruiting
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Duke Cancer Institute Cary, Cary, North Carolina +4 locations
Conditions: Oligometastasis, Metastatic Cancer
Register for Updates
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: START Midwest, Grand Rapids, Michigan +1 locations
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer
Register for Updates
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358
Recruiting
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Gender:
All
Ages:
12 years and above
Trial Updated:
03/12/2024
Locations: Alabama Oncology, Birmingham, Alabama +165 locations
Conditions: Solid Tumor, Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Register for Updates
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
NCT05475171
Recruiting
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer, Cervical Cancer
Register for Updates
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Mayo Clinic, Phoenix, Arizona +8 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Niraparib in Tumors Metastatic to the CNS
NCT04992013
Recruiting
This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). This research study involves the study drug niraparib.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Metastatic Cancer, Central Nervous System Cancer
Register for Updates
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
NCT05204147
Recruiting
This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in the body (advanced). Ac225-DOTA-M5A is a humanized monoclonal anti-CEA antibody, linked to a radioactive agent called actinium 225. M5A attaches to CEA positive cancer cells in a targeted way and delivers actinium 225 to kill them.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +10 locations
Conditions: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
Register for Updates
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT05076760
Recruiting
This phase I trial is designed in two parts. First as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is accessible for injection will undergo intratumoral injection of MEM-288. Following completion of the monotherapy study portion of the study, an expansion arm is desig... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
Register for Updates
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
NCT05010031
Recruiting
This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2024
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Cancer
Register for Updates